Use of inhaled nitric oxide in preterm infants.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24379225.
- Also identified by DOI 10.1542/peds.2013-3444.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nitric oxide, an important signaling molecule with multiple regulatory effects throughout the body, is an important tool for the treatment of full-term and late-preterm infants with persistent pulmonary hypertension of the newborn and hypoxemic respiratory failure. Several randomized controlled trials have evaluated its role in the management of preterm infants ≤ 34 weeks' gestational age with varying results. The purpose of this clinical report is to summarize the existing evidence for the use of inhaled nitric oxide in preterm infants and provide guidance regarding its use in this population.
Medical subject headings
- Bronchodilator Agents
- Infant, Premature, Diseases
- Nitric Oxide
- Persistent Fetal Circulation Syndrome
- Respiratory Insufficiency